OP Asset Management Ltd Takes $536,000 Position in Ralliant Corporation $RAL

OP Asset Management Ltd purchased a new position in shares of Ralliant Corporation (NYSE:RAL) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 12,899 shares of the company’s stock, valued at approximately $536,000.

Several other large investors have also recently added to or reduced their stakes in the company. Viking Global Investors LP purchased a new stake in Ralliant in the 2nd quarter valued at approximately $257,200,000. State Street Corp acquired a new stake in shares of Ralliant in the 2nd quarter valued at approximately $213,096,000. Millennium Management LLC grew its holdings in Ralliant by 172.4% during the fourth quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after acquiring an additional 3,147,660 shares during the period. Norges Bank purchased a new position in Ralliant in the fourth quarter worth $124,687,000. Finally, Invesco Ltd. raised its position in Ralliant by 90.1% in the third quarter. Invesco Ltd. now owns 3,871,690 shares of the company’s stock worth $169,309,000 after acquiring an additional 1,835,128 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have commented on RAL. Truist Financial restated a “buy” rating and set a $68.00 target price (up from $53.00) on shares of Ralliant in a research report on Wednesday, May 13th. Zacks Research upgraded shares of Ralliant from a “strong sell” rating to a “hold” rating in a research note on Monday, April 13th. Royal Bank Of Canada boosted their price objective on shares of Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a report on Wednesday, May 13th. Evercore started coverage on shares of Ralliant in a research report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 target price on the stock. Finally, Wall Street Zen downgraded shares of Ralliant from a “buy” rating to a “hold” rating in a research report on Sunday. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Ralliant has an average rating of “Moderate Buy” and a consensus price target of $69.00.

Ralliant Stock Performance

NYSE:RAL opened at $73.72 on Wednesday. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. The firm has a 50-day moving average price of $59.20 and a two-hundred day moving average price of $51.56. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $75.41. The company has a market capitalization of $8.25 billion and a P/E ratio of -6.74.

Ralliant (NYSE:RAL) last posted its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. The firm had revenue of $534.60 million for the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm’s quarterly revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, research analysts expect that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were issued a dividend of $0.05 per share. The ex-dividend date was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant’s payout ratio is -1.83%.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.